The British journal of psychiatry : the journal of mental science
Audio Summaries

School-based intervention study examining universal approaches for depressive symptoms and mental health literacy of pupils in Year 9 in England (AWARE): multi-school, parallel group, cluster randomised controlled trial

Aug 7, 2026

The AWARE trial aimed to evaluate the effectiveness of two universal school-based interventions, Youth Aware of Mental Health (YAM) and The Mental Health and High School Curriculum Guide (The Guide), in reducing depressive symptoms and improving mental health literacy among Year 9 pupils in England. While The Guide was found to increase intended help-seeking behaviors, neither intervention showed a reduction in depressive symptoms, with both associated with increased scores at long-term follow-up. The authors suggest that further investigation is needed to understand the potential negative impacts of these programs before wider implementation in schools.

Escitalopram and brain reactivity to aggressive stimuli in premenstrual dysphoric disorder

Jul 28, 2026

This study aimed to evaluate the effects of intermittent escitalopram treatment on symptoms of premenstrual dysphoric disorder (PMDD), specifically focusing on mood, aggressiveness, and neural responses to aggression-related stimuli. The findings indicate that escitalopram significantly reduced PMDD symptoms, particularly irritability and anger, and was associated with decreased aggressiveness and lower neural reactivity to provocation in brain regions linked to threat detection. Overall, the results support escitalopram's efficacy in treating PMDD and suggest its impact on neural circuits related to emotional regulation.

Exploring ageing as a potential new therapeutic target for schizophrenia

Jul 27, 2026

The authors investigate whether the biological changes associated with aging could serve as a new therapeutic target for schizophrenia. They propose that schizophrenia may be part of a broader spectrum of brain disorders linked to a multisystemic premature aging phenotype, similar to Alzheimer's and Parkinson's diseases. This research aims to explore the potential connections between aging and schizophrenia to inform future treatment strategies.

Intrinsic connectivity networks during fear and safety learning in youth

Jul 27, 2026

The authors investigate how intrinsic connectivity networks, particularly the default mode network, function during fear learning in young adults with and without mild mixed affective complaints. They aim to identify neural targets for potential treatments by comparing connectivity changes across different groups during a fear-conditioning paradigm. The findings reveal that individuals with subclinical mixed psychopathology show impaired differentiation between fear and safety stimuli, highlighting the role of the default mode network in affective disorders.

Childhood attention-deficit hyperactivity disorder traits and experiences of intimate partner violence up to midlife: evidence from a longitudinal cohort over five decades

Jul 23, 2026

This study investigates the long-term relationship between childhood attention-deficit hyperactivity disorder (ADHD) traits and experiences of intimate partner violence (IPV) by midlife. Utilizing data from the 1970 British Cohort Study, the authors found that individuals with higher ADHD traits in childhood are at an increased risk of experiencing various forms of IPV as adults. The findings underscore the importance of identifying and supporting individuals with ADHD to mitigate their vulnerability to interpersonal harm.

The changing landscape of autism diagnostic assessments in the UK

Jul 23, 2026

The authors investigate the impact of rising demand for autism diagnostic assessments in the UK on the quality of these evaluations within the National Health Service (NHS) and private sectors. They highlight concerns that cost-driven adaptations to assessment processes may lead to misdiagnosis and inadequate support, ultimately increasing the need for reassessments and exacerbating long-term burdens on individuals and healthcare services.

Social withdrawal among university students in the UK: the emerging hikikomori phenomena

Jul 20, 2026

The authors aim to investigate the prevalence of hikikomori and hikikomori-like behaviors among university students in the UK, as well as their associations with mental health issues, neurodevelopmental traits, and gaming disorder. Their findings reveal that approximately 21% of students exhibit some form of hikikomori behavior, with significant correlations to psychological distress, autism-related traits, and gaming disorder. The study highlights the need for early intervention strategies to address social withdrawal in young adults, particularly in relation to gaming and mental health challenges.

A Phase 2 randomised, double-blind, placebo-controlled trial of emestedastat in patients with major depressive disorder and cognitive impairment

Jul 17, 2026

The XanaCIDD trial aimed to evaluate the efficacy of emestedastat, a cortisol synthesis inhibitor, in improving cognitive impairment and depression in patients with major depressive disorder (MDD) and cognitive deficits. The study found no significant improvement in cognitive function at the primary endpoint, although there were trends suggesting potential antidepressant effects on secondary measures of depression. These results indicate that while emestedastat did not enhance cognitive outcomes, it may warrant further exploration as a novel antidepressant treatment.

Symptom-oriented clinical psychiatry

Jul 17, 2026

The author, Jian Hu, explores the question of how to enhance psychiatric care by emphasizing symptoms over traditional syndromic diagnoses. The editorial proposes a symptom-oriented clinical psychiatry framework that aims to clarify symptom roles, prioritize treatment, and minimize unnecessary medication, while still aligning with established diagnostic systems.

UK's regulatory and legislative double standards in the treatment of psychedelics and drugs for assisted suicide

Jul 17, 2026

This editorial by Ruslan Zinchenko examines the UK's inconsistent regulatory approach towards psychedelics and drugs intended for assisted suicide. The author questions why assisted suicide drugs can circumvent standard regulations despite limited evidence, while psychedelics, which show promising international results, face substantial barriers. Zinchenko argues for equal regulatory standards for both categories to facilitate clinical research and ensure patient safety.